A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01589510
First received: April 30, 2012
Last updated: July 8, 2013
Last verified: July 2013

April 30, 2012
July 8, 2013
April 2012
February 2013   (final data collection date for primary outcome measure)
Intraocular Pressure (IOP) [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01589510 on ClinicalTrials.gov Archive Site
  • Physician Assessment of Effect on IOP [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
  • Patient Assessment of Tolerability [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
  • Physician Assessment of Tolerability [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Patients who Discontinued Treatment [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Patients who Continued Treatment [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Patients who Maintained Compliance with Treatment [ Time Frame: 14 Weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Not Provided

A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with POAG and OHT

  • Glaucoma, Open-Angle
  • Ocular Hypertension
Drug: bimatoprost 0.01% ophthalmic solution
Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice.
Other Name: Lumigan® 0.01%
Lumigan® 0.01%
Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice.
Intervention: Drug: bimatoprost 0.01% ophthalmic solution
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
419
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of POAG or OHT
  • Prescribed Lumigan® 0.01%

Exclusion Criteria:

  • None
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
NCT01589510
MAF/AGN/OPH/GLA/034
No
Allergan
Allergan
Not Provided
Study Director: Medical Director Allergan
Allergan
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP